Search clinical trials for: REGN2477 REGN1033

Total 55 results

Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Withdrawn

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodyplasia Ossificans Progressiva (FOP) | Heterotopic Ossification (HO)
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss (COURAGE)

Obesity

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Sarcopenia

United States, Spain, Netherlands, France
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Regeneron Pharmaceuticals

Terminated

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Regeneron Pharmaceuticals

Completed

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Neovascular Wet Age-related Macular Degeneration (AMD)

United States
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Recruiting

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

COVID-19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

COVID-19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

COVID-19

United States
Regeneron Pharmaceuticals

Completed

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Regeneron Pharmaceuticals

Active, not recruiting

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

NSCLC

United States, France, Korea, Republic of
Regeneron Pharmaceuticals

Terminated

Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

Back Pain

United States
Regeneron Pharmaceuticals

Terminated

Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Abdominal Pain Upper

United States
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Healthy Volunteers

Germany, Belgium
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

COVID-19

United States, Mexico, Romania, Brazil, Chile, Moldova, Republic of
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Venous Thromboembolism

Poland, Latvia, Canada, Belgium, Bulgaria, Hungary, Lithuania
Regeneron Pharmaceuticals
Department of Health and Human Services

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Sciatica

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Regeneron Pharmaceuticals

Completed

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Withdrawn

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Osteoarthritis
Regeneron Pharmaceuticals

Completed

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

Osteoarthritis of the Knee

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Low Back Pain

United States, Poland, Canada, Hungary, Denmark, Estonia, Czechia
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Regeneron Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

COVID-19

United States, Mexico, Romania
Regeneron Pharmaceuticals

No longer available

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

COVID-19
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease

3

Subscribe